Collectively, histopathological analysis across multiple organs demonstrates that topical CCL3 treatment, even at 10-fold higher dose, does not induce systemic organ toxicity or exacerbate diabetes-associated tissue pathology, supporting its favorable safety profile in this model. Here, CCL3 is linked to diabetes mellitus.